[go: up one dir, main page]

AR089028A1 - Composiciones y metodos para el analisis de cancer de prostata - Google Patents

Composiciones y metodos para el analisis de cancer de prostata

Info

Publication number
AR089028A1
AR089028A1 ARP120104485A ARP120104485A AR089028A1 AR 089028 A1 AR089028 A1 AR 089028A1 AR P120104485 A ARP120104485 A AR P120104485A AR P120104485 A ARP120104485 A AR P120104485A AR 089028 A1 AR089028 A1 AR 089028A1
Authority
AR
Argentina
Prior art keywords
methods
compositions
cancer prostate
analysis
prostate analysis
Prior art date
Application number
ARP120104485A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR089028A1 publication Critical patent/AR089028A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90287—Oxidoreductases (1.) oxidising metal ions (1.16)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Proporciona métodos para diagnosticar el cáncer de próstata. También proporciona anticuerpos anti-STEAP-1 (Antígeno epitelial de seis dominios transmembrana de la próstata 1) y los usos de estos. Célula (hibridoma), ADN, kit.
ARP120104485A 2011-11-29 2012-11-29 Composiciones y metodos para el analisis de cancer de prostata AR089028A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629886P 2011-11-29 2011-11-29
US201261703099P 2012-09-19 2012-09-19

Publications (1)

Publication Number Publication Date
AR089028A1 true AR089028A1 (es) 2014-07-23

Family

ID=47324459

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104485A AR089028A1 (es) 2011-11-29 2012-11-29 Composiciones y metodos para el analisis de cancer de prostata

Country Status (15)

Country Link
US (2) US20130143237A1 (es)
EP (1) EP2786151B1 (es)
JP (1) JP6219304B2 (es)
KR (1) KR101951514B1 (es)
CN (1) CN104067127A (es)
AR (1) AR089028A1 (es)
AU (1) AU2012345926A1 (es)
BR (1) BR112014012882A2 (es)
CA (1) CA2854042A1 (es)
IL (1) IL232466A (es)
MX (1) MX350807B (es)
RU (1) RU2641968C2 (es)
SG (1) SG11201402711SA (es)
WO (1) WO2013082249A2 (es)
ZA (1) ZA201403110B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646661A (zh) * 2014-03-24 2016-06-08 朱育盼 特异性结合前列腺癌的短肽pcp2及其应用
CN108064343B (zh) * 2015-04-21 2021-07-09 基因泰克公司 用于前列腺癌分析的组合物和方法
CN110494452B (zh) 2017-04-03 2023-08-25 豪夫迈·罗氏有限公司 结合steap-1的抗体
CN108179134B (zh) * 2017-12-27 2020-11-24 武汉大学 基于EpCAM/PSMA双抗体功能化微流控芯片及其制备方法和应用
CA3104386A1 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
US20220348686A1 (en) * 2019-09-05 2022-11-03 Memorial Sloan Kettering Cancer Center Anti-steap1 antibodies and uses thereof
BR102020013625A2 (pt) * 2020-07-02 2022-01-11 Universidade Federal de Uberlândia Aptâmero modificado, sistema aptaimunológico, painel aptaimunológico, kit, método e uso no diagnóstico de câncer de próstata

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1062515B1 (en) 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
JP4855577B2 (ja) 1998-06-01 2012-01-18 アジェンシス，インコーポレイテッド ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2003065042A1 (en) 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2443996T3 (es) * 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP2061814B1 (en) * 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CN101652484B (zh) * 2006-11-08 2013-03-20 密歇根大学董事会 前列腺癌标志物spink1及其应用
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
US8445225B2 (en) 2008-09-05 2013-05-21 The Scripps Research Institute Methods for the detection of circulating tumor cells
AU2011239569B2 (en) * 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors

Also Published As

Publication number Publication date
IL232466A (en) 2017-10-31
SG11201402711SA (en) 2014-06-27
AU2012345926A1 (en) 2014-05-29
RU2641968C2 (ru) 2018-01-23
JP2015507175A (ja) 2015-03-05
CA2854042A1 (en) 2013-06-06
US20130143237A1 (en) 2013-06-06
MX350807B (es) 2017-09-20
BR112014012882A2 (pt) 2017-06-13
ZA201403110B (en) 2017-06-28
EP2786151B1 (en) 2019-07-03
EP2786151A2 (en) 2014-10-08
MX2014006187A (es) 2014-06-23
KR101951514B1 (ko) 2019-02-22
US20160274116A1 (en) 2016-09-22
CN104067127A (zh) 2014-09-24
US9632091B2 (en) 2017-04-25
JP6219304B2 (ja) 2017-10-25
IL232466A0 (en) 2014-06-30
KR20140100544A (ko) 2014-08-14
WO2013082249A2 (en) 2013-06-06
RU2014126358A (ru) 2016-01-27
WO2013082249A3 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
AR088941A1 (es) Anticuerpos anti-fgfr2 y sus usos
AR089028A1 (es) Composiciones y metodos para el analisis de cancer de prostata
CY1122543T1 (el) Δεσμευοντα μορια για bcma και cd3
AR089178A1 (es) Anticuerpos anti-il-36r
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
AR069681A1 (es) Moleculas de union al receptor ox40 humano
AR065420A1 (es) Anticuerpos anti-il-23 p19 de ingenieria
EA201492101A1 (ru) Антитела против fcrn
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
UY35456A (es) Moléculas de unión para bcma y cd3
CL2015002526A1 (es) Anticuerpos anti-ox40 y métodos de uso de los mismos.(divisional de 545-13).
GB201020995D0 (en) Biological materials and uses thereof
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
CU20170023A7 (es) Anticuerpos y receptores de antígeno quiméricos específicos para cd19
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
BR112012023010A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
EA201400875A1 (ru) Антитела к cd47 и способы их применения
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
MX366965B (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
EA201400447A1 (ru) АНТИТЕЛА К CD1d

Legal Events

Date Code Title Description
FB Suspension of granting procedure